Navigation Links
NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
Date:11/9/2009

SAN DIEGO, Nov. 9 /PRNewswire/ -- NexBio, Inc. announced the presentation of new data at the 2009 annual American College of Allergy, Asthma, and Immunology in Miami, Florida. The presentation was entitled "DAS181 (Fludase®), a Sialidase, Decreases Airway Resistance and Has Potent Anti-inflammatory Effects in Animal Models of Asthma".

DAS181 (Fludase®) is an investigational broad spectrum host-targeting drug candidate being studied in human clinical development for treatment and prevention of Influenza-Like Illness caused by any strains of influenza and parainfluenza. NexBio has recently announced the publication of two articles describing activity in non-clinical models of DAS181 for Pandemic Influenza A(H1N1) and for influenza resistant to Neuraminidase inhibitors (NAI), in a peer-reviewed journal.

The new data presented from studies in three animal models of asthma, done by NexBio's academic collaborators, demonstrate that DAS181 inhibits airway hyperreactivity, characteristic of asthma. DAS181 further decreases the number of inflammatory cells and mucous secreting cells in the respiratory tract. In the animal models, DAS181 is as effective as a bronchodilator or a steroid which are anti-asthma drugs on the market. People with asthma are prone to develop severe complications when they catch influenza. According to the Centers for Disease Control and Prevention (CDC), the majority of hospitalizations from the ongoing H1N1 Pandemic are in people with asthma.

The data were presented by Dr. Ronald Moss, NexBio's EVP of Clinical Development and Medical Affairs. "These data support the unique dual activities of DAS181. Because of its antiviral and anti-asthmatic properties, DAS181 may provide an alternative influenza treatment option for people with asthma and pre-existing respiratory diseases. This may be of a particular importance as there is increasing prevalence of drug resistance to Tamiflu®
'/>"/>

SOURCE NexBio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
2. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
3. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
4. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
10. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
11. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will webcast its ... on Monday, April 21, 2008 at 8:30 a.m. ET/5:30,a.m. ... will lead the call. On the same date pre-market, ... 2008., The call will be webcast live through ...
... 15 Excalibur, the new,international investment house launched ... of PIramed to Roche., (Photo: http://www.newscom.com/cgi-bin/prnh/20080415/301189 ... Roche for $185 million means a ,very substantial,cash ... fund created by Sir,Christopher five years ago., ...
... CALGARY, April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ... by Dr. Anders,Kolb of the Nemours Center for ... for Pediatric Sarcomas" was,presented today at the American ... is being held in San Diego, California from,April ...
Cached Biology Technology:Amylin Pharmaceuticals to Webcast First Quarter Results 2Excalibur Celebrates PIramed Sale With 'Substantial Cash Return' to Investors 2Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2
(Date:4/24/2014)... Initial treatment for a brain infection caused by fungus could ... due to study by University of Liverpool scientists. , ... often fatal but are relatively neglected in medical research. ... Africa, Australasia and South East Asia and mainly affect people ... people a year. , The University research team has tested ...
(Date:4/24/2014)... Researchers from North Carolina State University and the University ... new ultrasound device that could help identify arterial plaque ... causing heart attack or stroke. , At issue is ... age. Some types of plaque are deemed "vulnerable," meaning ... artery wall and cause heart attack or stroke. , ...
(Date:4/24/2014)... home from Iraq and Afghanistan, post-traumatic stress disorder (PTSD) ... and the culture at-large. Estimates indicate that as many ... Afghanistan suffer from PTSD. New research from the University ... on how PTSD is linked to other diseases in ... has implications beyond the impact of the psychiatric disorder ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2New ultrasound device may add in detecting risk for heart attack, stroke 2New study links inflammation in those with PTSD to changes in microRNA 2New study links inflammation in those with PTSD to changes in microRNA 3
... This press release is available in German . ... a UFZ German scientist found that the worldwide ... pollinators, bees mainly, was 153 billion in 2005 for ... amounted to 9.5% of the total value of the ...
... been referred to as an "essential toxin" due to ... between the nutritious requirement and toxic effects upon exposure. ... have lead to the characterization of selenium as a ... narrow threshold concentration in ecosystems through anthropogenic activities. Ironically, ...
... Journalists are invited to attend the 20th EORTCNCIAACR ... Geneva, Switzerland [Geneva Palexpo, Geneva] from Tuesday 21 ... is the deadline for booking accommodation via the ... this symposium, organised jointly by the European Organisation ...
Cached Biology News:Economic value of insect pollination worldwide estimated at 153 billion euros 2Economic value of insect pollination worldwide estimated at 153 billion euros 3Biological selenium removal: The solution to pollution? 2Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics 2